Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Dyne Therapeutics, Inc. has received an average rating of "Moderate Buy" from eighteen brokerages, with a twelve-month price target averaging $34.07.
• The company's stock currently trades at $17.12, with a market capitalization of $2.44 billion and a 1-year high of $35.68.
• CEO John Cox sold 2,640 shares of Dyne Therapeutics stock recently, representing a 1.31% decrease in his ownership position.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned an average rating of "Moderate Buy" from the eighteen brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, ten have given a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $34.0667.

Several brokerages recently issued reports on DYN. Royal Bank Of Canada reduced their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, July 29th. Stifel Nicolaus cut their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Chardan Capital dropped their price objective on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, July 29th. Evercore ISI reiterated an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $17.12 on Friday. The company's 50 day simple moving average is $13.80 and its 200 day simple moving average is $11.76. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -4.44 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $35.68.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 2,640 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer directly owned 199,539 shares of the company's stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 14.14% of the company's stock.

Institutional Trading of Dyne Therapeutics

A number of large investors have recently bought and sold shares of the business. Darwin Wealth Management LLC lifted its stake in shares of Dyne Therapeutics by 0.5% in the 3rd quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company's stock worth $2,195,000 after acquiring an additional 861 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Dyne Therapeutics by 11.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock valued at $91,000 after acquiring an additional 955 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock valued at $237,000 after acquiring an additional 1,115 shares in the last quarter. Arizona State Retirement System increased its holdings in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after acquiring an additional 1,481 shares in the last quarter. Finally, Caxton Associates LLP grew its holdings in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock worth $158,000 after buying an additional 1,627 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.